Oneil Bains, MD
Pulmonary Disease · Seattle, WANPI 1982712584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,072 of the $156,459 with a category attached, or 72.3%. Jazz Pharmaceuticals Inc. accounts for 77.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $59,238, more than ten times the $2,876 reported in 2019. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $686.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$120K
- Axsome Therapeutics, Inc.$24K
- Harmony Biosciences LLC$6K
- Avadel CNS Pharmaceuticals, LLC$5K
- Inspire Medical Systems, Inc.$1K
- ZOLL Respicardia, Inc.$262
- plus $223 from 2 others
What the payments were for
- Consulting fees$22,97115%
- Speaking & faculty fees$113,07272%
- Travel & lodging$11,1817%
- Food & beverage$9,0936%
- Education$1230%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 135 | $120,484 |
| Axsome Therapeutics, Inc. | 33 | $23,652 |
| Harmony Biosciences LLC | 28 | $5,979 |
| Avadel CNS Pharmaceuticals, LLC | 13 | $4,605 |
| Inspire Medical Systems, Inc. | 14 | $1,255 |
| ZOLL Respicardia, Inc. | 2 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $204 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$115,249
- SUNOSI$25,942
- Wakix$5,460
- LUMRYZ$4,294
- Inspire$825
- XYREM$451
- remede System$262
- Inspire Upper Airway Stimulation System$136
How this compares
$156,459 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 62 | $1,053,217 |
| Sodium Oxybate | 45 | $818,862 |
| XyremSodium Oxybate | 32 | $633,937 |
| DayvigoLemborexant | 21 | $9,256 |
| Armodafinil | 60 | $5,402 |
| Modafinil | 62 | $4,926 |
| Doxepin Hcl | 23 | $4,240 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 20 | $4,188 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 184 | $3,276 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 87 | $3,035 |
| Zolpidem Tartrate | 331 | $2,993 |
| Zaleplon | 67 | $2,899 |
| Methylphenidate Hcl | 66 | $2,536 |
| Pregabalin | 134 | $2,523 |
| Eszopiclone | 121 | $2,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Dayvigo | $19 | $9,25621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Seattle
- Jed GordenSeattle$236K
- Ganesh RaghuSeattle$147K
- Jeffrey CarySeattle$106K
- Amy DickeySeattle$71K
- Lawrence HoSeattle$70K
- Christopher GossSeattle$44K
- Reena MehraSeattle$36K
- Rebecca SellSeattle$30K
- Peter LearySeattle$27K
- Mark WurfelSeattle$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.